METFORMIN USE AND THE RATES OF DEVELOPMENT OF HYPERTENSIVE DISEASE OF PREGNANCY IN GRAVIDAE WITH POLYCYSTIC OVARY SYNDROME (PCOS)

Abstract

Gravidae with PCOS have higher incidences of hypertensive complications including gestational hypertension (gHTN) and pre-eclampsia (PE). Studies have shown that metformin may reduce rates of hypertensive disease in gravidae with PCOS and/or obesity [1,2]. However, these studies may fail to account for concurrent aspirin (ASA) use, as daily use of 81 mg of ASA after 12 weeks in pregnancy can prevent or delay the development of PE in these same at-risk women [3]. Thus, we sought to better understand the relationship between metformin use with and without ASA use, and rates of development of gHTN and PE in gravidae with PCOS.